Skip to content
Research Article Open access CC BY 4.0

The Use of Ophthalmic and Nasal Naphazoline in the Outpatient Setting

Nehad Jaser Ahmed, Hasan Soliman Yusufoglu

Journal of Pharmaceutical Research International · pp. 19–23 · Published 21 Dec 2021

10.9734/jpri/2021/v33i60B34580

Abstract

Aim: The present study aimed to describe the use of ophthalmic and nasal naphazoline in the outpatient setting. Methodology: This was a retrospective study that includes reviewing the electronic prescriptions of naphazoline among outpatients in a public hospital in Alkharj. Results: During the study period of 6 months, 393 patients received naphazoline. Most of them were male patients (77.35%) and the age of 34.35% of them was between 20 and 29 years. The majority of the prsecriptions that contained naphazoline were prescribed by residents (99.75%). Most of the patients received naphazoline as nasal drops either alone (47.84%) or combined with chlorpheniramine (36.13%). The majority of the prescriptions were written by the emergency department (99.24%). Conclusion: The present study showed that naphazoline was commonly prescribed in Alkharj. Further studies are needed to explore the frequency and pattern of naphazoline use as well as to explore the frequency of prescribing other sympathomimetic vasoconstrictors in different settings.

Naphazoline nasal ophthalmic outpatient use

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.